Granulocyte colony-stimulating factor for poor graft function after allogeneic stem cell transplantation: 3 days of G-CSF identifies long-term responders
- PMID: 15980881
- DOI: 10.1038/sj.bmt.1705072
Granulocyte colony-stimulating factor for poor graft function after allogeneic stem cell transplantation: 3 days of G-CSF identifies long-term responders
Abstract
Poor graft function (PGF) is a frequent cause of morbidity after allogeneic hematopoietic stem cell transplantation (allo-HSCT). To study the value of granulocyte colony-stimulating factor (G-CSF) in PGF, we retrospectively analyzed 81 episodes of PGF in 66 patients transplanted from 01/94 to 01/99 from an HLA-identical sibling (n = 45) or an unrelated (n = 21) donor. Median age was 29 years, 55 patients had malignancies. A total of 11 patients received a CD34+ selected graft. Viral infections (25%), myelotoxic drug (33%), fungal/bacterial infections (14%), and GVHD (31%) were present before PGF diagnosis. Median time from allo-HSCT to PGF was 75 (25-474) days. All patients were treated with G-CSF. In 77/81 episodes, there was a response that was sustained in 57. A total of 27 patients presented an increase of white cell count (WBC) >0.1 x 10(9)/l after 3 days of G-CSF. The 5-year survival was 37% and was significantly better in patients with increased WBC > 0.1 x 10(9)/l after 3 days of G-CSF (65 vs 18%, P < 0.0001). In multivariate analysis, increased WBC > 0.1 x 10(9)/l after 3 days of G-CSF (P = 0.002) was associated with better survival, while BuCy-based conditioning (P = 0.02) and GVHD (P = 0.005) were associated with higher risk of death. In conclusion, hematological response after 3 days with G-CSF predicted a better survival for patients with PGF after allo-SCT.
Similar articles
-
Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.Biol Blood Marrow Transplant. 2009 Feb;15(2):266-73. doi: 10.1016/j.bbmt.2008.11.029. Biol Blood Marrow Transplant. 2009. PMID: 19167687 Clinical Trial.
-
Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation.Bone Marrow Transplant. 2001 Mar;27(5):499-505. doi: 10.1038/sj.bmt.1702816. Bone Marrow Transplant. 2001. PMID: 11313683 Clinical Trial.
-
G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV.Bone Marrow Transplant. 2003 Jul;32(2):217-23. doi: 10.1038/sj.bmt.1704108. Bone Marrow Transplant. 2003. PMID: 12838288
-
Optimal use of G-CSF administration after hematopoietic SCT.Bone Marrow Transplant. 2009 Jun;43(12):895-908. doi: 10.1038/bmt.2009.75. Epub 2009 Apr 13. Bone Marrow Transplant. 2009. PMID: 19363527 Review.
-
[Collection of hematopoietic progenitor cells from healthy donors].Acta Med Croatica. 2009 Jun;63(3):237-44. Acta Med Croatica. 2009. PMID: 19827352 Review. Croatian.
Cited by
-
Haploidentical donor transplant is associated with secondary poor graft function after allogeneic stem cell transplantation: A single-center retrospective study.Cancer Med. 2021 Dec;10(23):8497-8506. doi: 10.1002/cam4.4353. Epub 2021 Oct 20. Cancer Med. 2021. PMID: 34668661 Free PMC article.
-
Eltrombopag for the Treatment of Allogeneic Hematopoietic Stem Cell Transplantation-Related Poor Graft Function.Cureus. 2023 Sep 2;15(9):e44555. doi: 10.7759/cureus.44555. eCollection 2023 Sep. Cureus. 2023. PMID: 37790070 Free PMC article.
-
Eltrombopag Enhances Recovery from Cytopenias Due to Poor Graft Function after Hematopoietic Cell Transplantation.Blood Cell Ther. 2025 Jan 24;8(1):160-166. doi: 10.31547/bct-2024-017. eCollection 2025 Feb 25. Blood Cell Ther. 2025. PMID: 40061175 Free PMC article.
-
Uric acid as a novel biomarker for bone-marrow function and incipient hematopoietic reconstitution after aplasia in patients with hematologic malignancies.J Cancer Res Clin Oncol. 2017 May;143(5):759-771. doi: 10.1007/s00432-017-2348-z. Epub 2017 Feb 16. J Cancer Res Clin Oncol. 2017. PMID: 28210842 Free PMC article.
-
Febuxostat-induced agranulocytosis in a pediatric hematopoietic stem cell transplant recipient: Case Report and literature review.Front Pharmacol. 2024 Oct 23;15:1478381. doi: 10.3389/fphar.2024.1478381. eCollection 2024. Front Pharmacol. 2024. PMID: 39508043 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials